Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Finished Goods (2016 - 2025)

Heron Therapeutics' Finished Goods history spans 10 years, with the latest figure at $6.9 million for Q4 2025.

  • For Q4 2025, Finished Goods rose 10.36% year-over-year to $6.9 million; the TTM value through Dec 2025 reached $6.9 million, up 10.36%, while the annual FY2025 figure was $6.9 million, 10.36% up from the prior year.
  • Finished Goods reached $6.9 million in Q4 2025 per HRTX's latest filing, down from $10.9 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $22.0 million in Q3 2022 to a low of $6.2 million in Q4 2024.
  • Average Finished Goods over 5 years is $11.6 million, with a median of $9.9 million recorded in 2023.
  • The largest YoY upside for Finished Goods was 319.6% in 2021 against a maximum downside of 61.07% in 2021.
  • A 5-year view of Finished Goods shows it stood at $6.3 million in 2021, then soared by 199.22% to $18.7 million in 2022, then plummeted by 47.0% to $9.9 million in 2023, then tumbled by 37.11% to $6.2 million in 2024, then increased by 10.36% to $6.9 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Finished Goods are $6.9 million (Q4 2025), $10.9 million (Q3 2025), and $11.0 million (Q2 2025).